KIT and ovarian carcinoma: Given that CD44+CD117+ cells derived from the 2008 ovarian cancer cell line possess all CSC properties18, this result suggests that the ALDH1A1 inhibitor is also able to inhibit the ovarian cancer cell dedifferentiation.